Cyclerion Therapeutics, Inc.
Treatment of metabolic syndrome with an sGC stimulator

Abstract:

The present invention provides a method of treating a subject with metabolic syndrome by administering a stimulator of soluble guanylate cyclase (sGC) (Compound I) either alone or in combination therapy with a blood glucose lowering (antihyperglycemic or antidiabetes) medication, a blood pressure lowering (anti-hypertensive) medication, an anti-hyperlipidemic medication, or combinations thereof. It also relates to a method of reducing the level of a clinical marker selected from the group comprising of fasting blood glucose levels, fasting blood insulin levels, hemoglobin A1C (HbA1C) levels, blood cholesterol levels (total or LDL), blood ApoB levels, HOMA-IR levels, blood triglyceride levels, blood concentration of ADMA, blood levels of alanine transaminase, aspartate transaminase, and GGT, body weight and abdominal circumference, or any combination of these markers thereof, in a subject in need thereof by administering a stimulator of sGC (Compound I) either alone or in combination therapy with a blood glucose lowering (antihyperglycemic or antidiabetes) medication, a blood pressure lowering (anti-hypertensive) medication, an anti-hyperlipidemic medication, or combinations thereof.